- Home
- MTEX vs CLSD Comparison
MTEX vs CLSD Comparison
Compare MTEX & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEX
- CLSD
- Stock Information
- Founded
- MTEX 1993
- CLSD 2011
- Country
- MTEX United States
- CLSD United States
- Employees
- MTEX N/A
- CLSD N/A
- Industry
- MTEX Medicinal Chemicals and Botanical Products
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- MTEX Health Care
- CLSD Health Care
- Exchange
- MTEX Nasdaq
- CLSD Nasdaq
- Market Cap
- MTEX 18.2M
- CLSD 20.4M
- IPO Year
- MTEX 1999
- CLSD 2016
- Fundamental
- Price
- MTEX $9.84
- CLSD $0.89
- Analyst Decision
- MTEX
- CLSD Hold
- Analyst Count
- MTEX 0
- CLSD 4
- Target Price
- MTEX N/A
- CLSD $75.00
- AVG Volume (30 Days)
- MTEX 24.2K
- CLSD 295.3K
- Earning Date
- MTEX 11-12-2025
- CLSD 11-14-2025
- Dividend Yield
- MTEX N/A
- CLSD N/A
- EPS Growth
- MTEX N/A
- CLSD N/A
- EPS
- MTEX N/A
- CLSD N/A
- Revenue
- MTEX $110,411,000.00
- CLSD $3,329,000.00
- Revenue This Year
- MTEX N/A
- CLSD $98.20
- Revenue Next Year
- MTEX N/A
- CLSD $213.77
- P/E Ratio
- MTEX N/A
- CLSD N/A
- Revenue Growth
- MTEX N/A
- CLSD N/A
- 52 Week Low
- MTEX $7.50
- CLSD $0.80
- 52 Week High
- MTEX $16.49
- CLSD $17.10
- Technical
- Relative Strength Index (RSI)
- MTEX 57.80
- CLSD 18.68
- Support Level
- MTEX $9.34
- CLSD $2.54
- Resistance Level
- MTEX $9.86
- CLSD $4.00
- Average True Range (ATR)
- MTEX 0.39
- CLSD 0.33
- MACD
- MTEX 0.03
- CLSD -0.27
- Stochastic Oscillator
- MTEX 95.21
- CLSD 2.02
About MTEX Mannatech Incorporated
Mannatech Inc is a wellness solution provider. The company develops and sells nutritional supplements, topical and skin care and anti-aging products, and weight-management products that target optimal health and wellness. Mannatech sells products in three regions: the Americas (the United States, Canada, and Mexico); Europe/the Middle East/Africa (EMEA) (Austria, the Czech Republic, Denmark, Estonia, Finland, Germany, the Republic of Ireland, Namibia, the Netherlands, Norway, South Africa, Spain, Sweden, and the United Kingdom); and Asia/Pacific (Australia, Japan, New Zealand, the Republic of Korea, Singapore, Taiwan, Hong Kong, and China). Mannatech generates the majority of its revenue from the Americas.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing a proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.